it has been found to be active against drug susceptible as well as MDR

The preliminary response data of the initial 42 patients showed an ORR of 83-year. Single agent lenalidomide In a multicenter, open label phase II study of single agent lenalidomide in relapsed or refractory MM, patients were treated CX-4945 with either lenalidomide 30 mg once daily or 15 mg twice daily for 21 days of every 28 day period. An overall total of 56% of patients had received at the very least four prior lines of treatment, 61% had received prior high-dose chemotherapy followed by SCT, 76-year had received prior thalidomide, and 1 5 years had formerly received bortezomib. In the total cohort, the ORR to lenalidomide was 250-page, and an additional 29-oct of people responded with the addition of low dose dexamethasone, which was allowed after two cycles for progressive or stable disease. The mean length of response, Plastid with censoring at the time that dexamethasone was added, was 19 months. In the twice-daily group, the mean duration of reaction was 23 months. In a long-term follow up of 15 people who remained on treatment for a median of 4. 1 years, 11 had reached either CR or PR and continued to answer, including four of six patients receiving lenalidomide monotherapy, and seven of eight patients receiving concomitant dexamethasone. Stable disease was maintained by the remaining four patients with this long haul followup. A second multi-center, open-label study examined singleagent lenalidomide in patients with relapsed or refractory MM. Lenalidomide was given at 30 mg once daily on days 21 every 28 days until illness progression or intolerance. Concomitant dexamethasone was not granted. All patients had received at the very least two preceding therapies, including bortezomib, stem-cell transplantation, and thalidomide. The Oprozomib ORR was 26-year, using an additional 66th-minute of patients reaching stable illness. The average duration of response was 13 months. In a stage I dose escalation study of 27 patients who received lenalidomide being a single daily dose, 24 patients received at least 28 days of therapy and were deemed evaluable for response. 113 Seventeen patients had a most readily useful response of 250-room reduction in M protein, including seven patients who achieved?50% reduction. The median duration of response was six months and the time to response was two months. Lenalidomide plus doxorubicin Within the relapsed or refractory MM environment, lenalidomide has been investigated in a phase I/II study in conjunction with pegylated liposomal doxorubicin based chemotherapy. Sixty two people received liposomal doxorubicin 40 mg/m2 and vincristine 2 mg on day 1, dexamethasone 40 mg/day on days 4, and lenalidomide 15 mg/day on days 21 of each 28 day cycle. Among 52 evaluable patients, the ORR of the combination was 75-year, including 29-year of patients with whether CR or nCR. Most useful reaction occurred after a median of 115 days and four cycles of therapy.